From: Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Analysis Group | Cohort | N | HR (95% CI) | P Value | Reference |
---|---|---|---|---|---|
JELIS | All patients | 18,645 | 0.81 (0.69–0.95) | 0.011 | Yokoyama, 2007 [36] |
Impaired glucose metabolismb | All patients | 4565 | 0.78 (0.60–0.998) | 0.048 | Oikawa, 2009 [46] |
Peripheral artery disease | All patients | 223 | 0.44 (0.19–0.97) | 0.041 | Ishikawa, 2010 [47] |
JELIS | 1° prevention | 14,981 | 0.82 (0.63–1.06) | 0.132 | Yokoyama, 2007 [36] |
TG ≥150 mg/dL and/or HDL-C <40 mg/dL | 1° prevention | 957 | 0.47 (0.23–0.98) | 0.043 | Saito, 2008 [45] |
Patients not achieving LDL-C and non-HDL-C goalsc | 1° prevention | 6592 | 0.62 (0.43–0.88) | 0.007 | Sasaki, 2012 [48] |
JELIS | 2° prevention | 3664 | 0.81 (0.657–0.998) | 0.048 | Yokoyama, 2007 [36] |
Prior myocardial infarction | 2° prevention | 1050 | 0.73 (0.54–0.98) | 0.033 | Matsuzaki, 2009 [49] |
Prior coronary intervention | 2° prevention | 895 | 0.65 (0.48–0.89) | 0.007 | Matsuzaki, 2009 [49] |